Frontiers in Pharmacology (Oct 2023)
Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
- Lenka N. C. Boyd,
- Lenka N. C. Boyd,
- Lenka N. C. Boyd,
- Lynn E. Nooijen,
- Lynn E. Nooijen,
- Lynn E. Nooijen,
- Mahsoem Ali,
- Mahsoem Ali,
- Mahsoem Ali,
- Jisce R. Puik,
- Jisce R. Puik,
- Jisce R. Puik,
- Jasmine Moustaquim,
- Stephanie M. Fraga Rodrigues,
- Stephanie M. Fraga Rodrigues,
- Stephanie M. Fraga Rodrigues,
- Robert Broos,
- Robert Broos,
- Robert Broos,
- Ali Belkouz,
- Laura L. Meijer,
- Tessa Y. S. Le Large,
- Tessa Y. S. Le Large,
- Tessa Y. S. Le Large,
- Joris I. Erdmann,
- Gerrit K. J. Hooijer,
- Michal Heger,
- Michal Heger,
- Michal Heger,
- Hanneke W. M. Van Laarhoven,
- Hanneke W. M. Van Laarhoven,
- Eva Roos,
- Geert Kazemier,
- Geert Kazemier,
- Elisa Giovannetti,
- Elisa Giovannetti,
- Elisa Giovannetti,
- Joanne Verheij,
- Heinz-Josef Klümpen
Affiliations
- Lenka N. C. Boyd
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Lenka N. C. Boyd
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Lenka N. C. Boyd
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Lynn E. Nooijen
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Lynn E. Nooijen
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Lynn E. Nooijen
- Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Mahsoem Ali
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Mahsoem Ali
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Mahsoem Ali
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Jisce R. Puik
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Jisce R. Puik
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Jisce R. Puik
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Jasmine Moustaquim
- Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Stephanie M. Fraga Rodrigues
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Stephanie M. Fraga Rodrigues
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Stephanie M. Fraga Rodrigues
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Robert Broos
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Robert Broos
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Robert Broos
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Ali Belkouz
- Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Laura L. Meijer
- Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, Netherlands
- Tessa Y. S. Le Large
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Tessa Y. S. Le Large
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Tessa Y. S. Le Large
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Joris I. Erdmann
- Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Gerrit K. J. Hooijer
- Department of Pathology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Michal Heger
- Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, China
- Michal Heger
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
- Michal Heger
- 0Erasmus Medical Center, Laboratory for Experimental Oncology, Department of Pathology, Rotterdam, Netherlands
- Hanneke W. M. Van Laarhoven
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Hanneke W. M. Van Laarhoven
- Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Eva Roos
- 1Department of Pathology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- Geert Kazemier
- Department of Surgery, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Geert Kazemier
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Elisa Giovannetti
- Department of Medical Oncology, Lab of Medical Oncology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, Netherlands
- Elisa Giovannetti
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands
- Elisa Giovannetti
- 2Cancer Pharmacology Lab, Associazione Italiana per La Ricerca Sul Cancro (AIRC) Start-Up Unit, Fondazione Pisana per La Scienza, Pisa, Italy
- Joanne Verheij
- Department of Pathology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- Heinz-Josef Klümpen
- Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
- DOI
- https://doi.org/10.3389/fphar.2023.1274692
- Journal volume & issue
-
Vol. 14
Abstract
Introduction: Effective (neo) adjuvant chemotherapy for cholangiocarcinoma is lacking due to chemoresistance and the absence of predictive biomarkers. Human equilibrative nucleoside transporter 1 (hENT1) has been described as a potential prognostic and predictive biomarker. In this study, the potential of rabbit-derived (SP120) and murine-derived (10D7G2) antibodies to detect hENT1 expression was compared in tissue samples of patients with extrahepatic cholangiocarcinoma (ECC), and the predictive value of hENT1 was investigated in three ECC cell lines.Methods: Tissues of 71 chemonaïve patients with histological confirmation of ECC were selected and stained with SP120 or 10D7G2 to assess the inter-observer variability for both antibodies and the correlation with overall survival. Concomitantly, gemcitabine sensitivity after hENT1 knockdown was assessed in the ECC cell lines EGI-1, TFK-1, and SK-ChA-1 using sulforhodamine B assays.Results: Scoring immunohistochemistry for hENT1 expression with the use of SP120 antibody resulted in the highest interobserver agreement but did not show a prognostic role of hENT1. However, 10D7G2 showed a prognostic role for hENT1, and a potential predictive role for gemcitabine sensitivity in hENT1 in SK-ChA-1 and TFK-1 cells was found.Discussion: These findings prompt further studies for both preclinical validation of the role of hENT1 and histochemical standardization in cholangiocarcinoma patients treated with gemcitabine-based chemotherapy.
Keywords
- hENT1
- cholangiocarcinoma
- perihilar cholangiocarcinoma
- distal cholangiocarcinoma
- extrahepatic cholangiocarcinoma
- prognostic biomarker